Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2003

View Archived Issues

BENEFIT study in early MS completes enrollment

Encouraging phase II efficacy results for NCX-701 in acute pain

XL-784 enters first-in-man safety study

DOR BioPharma pursues second indication for orBec

ES-285 enters clinical development

Good safety profile and improved glycemic control reported for balaglitazone in type 2 diabetes

Rapid onset of action reported for a novel insulin analogue

Excellent treatment compliance reported for AERx(R) iDMS among diabetic patients

Dose-dependent improvements in glycemic control in diabetic rats and humans treated with exenatide

Pramlintide acetate improves glycemic control without increasing body weight

New LXR ligands and their use described by Merck researchers

Celltech scientists design novel p38 inhibitors for arthritis and other disorders

Yamanouchi prepares and tests new vasopressin V2 ligands

Isatoribine derivatives with improved pharmacokinetics reported by Anadys

GSK-3 inhibitors, their preparation and use covered by GSK patent

New antiestrogenic agents in early development at Schering AG

Two series of beta-secretase inhibitors revealed in recent patents

Novel inhibitors of CD23 production with utility in allergy, asthma, etc.

ZP-123 prevents ischemia-induced ventricular tachycardia via effects on gap junctions

Sterix presents first dual aromatase and steroid sulfatase inhibitor

Novel aquaretic and antivasopressor agent targeting both V1a and V2 receptors

Orally active nonsteroidal progesterone receptor antagonist PRA-248 characterized

FDA approves Reyataz for HIV-1 infection

FDA approval of Striant for testosterone replacement therapy

First humanized IgE-targeting antibody therapeutic approved for asthma

Manhattan and NovaDel begin propofol lingual spray program

Emisphere and U.S. Army sign CRADA for oral anthrax vaccine

VIC-acne completes phase I safety study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...